secwatch.observer — SEC 8-K summary
======================================

Issuer:     Climb Bio, Inc. (CLYM)
CIK:        0001768446
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-006994
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Climb Bio updates on budoprutug and CLYM116 trials; cash runway into 2028
-------------------------------------------------------------------------

- First patient dosed in PrisMN Phase 2 trial of budoprutug for primary membranous nephropathy (Nov 2025).
- Received China IND clearance for budoprutug in SLE; parallel China Phase 1b to enroll lupus nephritis patients (Dec 2025).
- Completed dosing of first cohort in Phase 1 trial of subcutaneous budoprutug and of CLYM116 in healthy volunteers (Dec 2025).
- Expects initial data from SC budoprutug Phase 1 (H1 2026), budoprutug pMN Phase 2 (H2 2026), and CLYM116 Phase 1 (mid-2026).
- Cash, cash equivalents, and marketable securities expected to fund operations into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526006994/0001193125-26-006994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768446/000119312526006994/d92848d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-006994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer